These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32514241)

  • 1. The cancer immunotherapy environment may confound the utility of anti-TIF-1γ in differentiating between paraneoplastic and treatment-related dermatomyositis. Report of a case and review of the literature.
    Zarkavelis G; Mauri D; Karassa F; Eleftherios K; Pentheroudakis G; Pappadaki A; Mavroeidis L; Ntellas P; Gkoura S; Gazouli I
    Contemp Oncol (Pozn); 2020; 24(1):75-78. PubMed ID: 32514241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dermatomyositis with anti-TIF-1γ antibodies as a presenting symptom of underlying triple-negative breast cancer: a case report.
    Kubeček O; Soukup T; Paulík A; Kopecký J
    BMC Cancer; 2016 Aug; 16(1):684. PubMed ID: 27561848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis.
    Fiorentino DF; Kuo K; Chung L; Zaba L; Li S; Casciola-Rosen L
    J Am Acad Dermatol; 2015 Mar; 72(3):449-55. PubMed ID: 25595720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small cell lung cancer and interstitial pneumonia associated with anti-transcriptional intermediary factor-1γ-positive dermatomyositis.
    Kato T; Ito S; Tsuzuki T; Watanabe D; Kubo A; Yamaguchi E
    Respirol Case Rep; 2019 May; 7(4):e00412. PubMed ID: 30906559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-TIF1γ antibody-positive dermatomyositis associated with nivolumab administration in a patient with advanced oesophageal squamous cell carcinoma: A case report and literature review.
    Sakurai T; Takahashi J; Komatsu T; Mitsumura H; Iguchi Y
    Mod Rheumatol Case Rep; 2023 Jun; 7(2):416-421. PubMed ID: 36715286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paraneoplastic dermatomyositis appearing after nivolumab therapy for gastric cancer: a case report.
    Shibata C; Kato J; Toda N; Imai M; Fukumura Y; Arai J; Kurokawa K; Kondo M; Takagi K; Kojima K; Ohki T; Seki M; Yoshida M; Suzuki A; Tagawa K
    J Med Case Rep; 2019 Jun; 13(1):168. PubMed ID: 31153385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Anti-transcriptional Intermediary Factor-1 Gamma Autoantibody in Identifying Adult Dermatomyositis Patients with Cancer: A Systematic Review and Meta-analysis.
    Best M; Molinari N; Chasset F; Vincent T; Cordel N; Bessis D
    Acta Derm Venereol; 2019 Mar; 99(3):256-262. PubMed ID: 30460368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ.
    Fiorentino DF; Chung LS; Christopher-Stine L; Zaba L; Li S; Mammen AL; Rosen A; Casciola-Rosen L
    Arthritis Rheum; 2013 Nov; 65(11):2954-62. PubMed ID: 24037894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Characteristics of Anti-TIF-1γ Antibody-Positive Dermatomyositis Associated with Malignancy.
    Harada Y; Tominaga M; Iitoh E; Kaieda S; Koga T; Fujimoto K; Chikasue T; Obara H; Kakuma T; Ida H; Kawayama T; Hoshino T
    J Clin Med; 2022 Mar; 11(7):. PubMed ID: 35407533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-TIF-1γ Antibody Detection Using a Commercial Kit vs In-House Immunoblot: Usefulness in Clinical Practice.
    Mariscal A; Milán M; Baucells A; Martínez MA; Guillen AG; Trallero-Araguás E; Alvarado-Cardenas M; Martínez-Martínez L; Alserawan L; Franco-Leyva T; Sanz-Martínez MT; Viñas-Giménez L; Corominas H; Juárez C; Castellví I; Selva-O'Callaghan A
    Front Immunol; 2020; 11():625896. PubMed ID: 33613568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case Report: IgA Nephropathy in a Patient With Anti-Transcription Intermediary Factor-1γ Antibody-Positive Dermatomyositis.
    Zhang S; Chen YL; Liu CL; Xie JY; Sun BD; Liu DZ
    Front Immunol; 2022; 13():757802. PubMed ID: 35185871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins.
    Fujimoto M; Hamaguchi Y; Kaji K; Matsushita T; Ichimura Y; Kodera M; Ishiguro N; Ueda-Hayakawa I; Asano Y; Ogawa F; Fujikawa K; Miyagi T; Mabuchi E; Hirose K; Akimoto N; Hatta N; Tsutsui K; Higashi A; Igarashi A; Seishima M; Hasegawa M; Takehara K
    Arthritis Rheum; 2012 Feb; 64(2):513-22. PubMed ID: 21987216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Rare Case of Anti-TIF-1γ Antibody Positive Dermatomyositis in Adulthood.
    Agrawal U; Sondhi M; Zamora Smith A; Nida SS; Umer S; Hayat S; Muzaffar K
    J Investig Med High Impact Case Rep; 2024; 12():23247096241263065. PubMed ID: 38904327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remarkable remission of symptomatic dermatomyositis after curative breast cancer surgery.
    Fujino M; Kawashima M; Yoshifuji H; Nakashima R; Yamada Y; Matsumoto Y; Kawaguchi-Sakita N; Mori Y; Pu F; Yamaguchi A; Kawaguchi K; Takada M; Toi M
    Int Cancer Conf J; 2024 Apr; 13(2):111-118. PubMed ID: 38524641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoantibody to transcriptional intermediary factor-1β as a myositis-specific antibody: clinical correlation with clinically amyopathic dermatomyositis or dermatomyositis with mild myopathy.
    Ueda-Hayakawa I; Hamaguchi Y; Okiyama N; Motegi S; Yamaoka T; Miyake S; Higashi A; Okamoto H; Takehara K; Fujimoto M
    Br J Dermatol; 2019 Apr; 180(4):881-887. PubMed ID: 30120913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Anti-Transcription Intermediary Factor 1γ Antibodies With Paraneoplastic Rheumatic Syndromes Other Than Dermatomyositis.
    Venalis P; Selickaja S; Lundberg K; Rugiene R; Lundberg IE
    Arthritis Care Res (Hoboken); 2018 Apr; 70(4):648-651. PubMed ID: 28704599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma.
    Scott ES; Long GV; Guminski A; Clifton-Bligh RJ; Menzies AM; Tsang VH
    Eur J Endocrinol; 2018 Feb; 178(2):173-180. PubMed ID: 29187509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oropharyngeal Dysphagia in Dermatomyositis: Associations with Clinical and Laboratory Features Including Autoantibodies.
    Mugii N; Hasegawa M; Matsushita T; Hamaguchi Y; Oohata S; Okita H; Yahata T; Someya F; Inoue K; Murono S; Fujimoto M; Takehara K
    PLoS One; 2016; 11(5):e0154746. PubMed ID: 27167831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymyositis and dermatomyositis as a risk of developing cancer.
    Jakubaszek M; Kwiatkowska B; Maślińska M
    Reumatologia; 2015; 53(2):101-5. PubMed ID: 27407235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of radioimmunoprecipitation versus antigen-specific assays for identification of myositis-specific autoantibodies in dermatomyositis patients.
    Kang EH; Kuwana M; Okazaki Y; Lee EY; Lee YJ; Lee EB; Song YW
    Mod Rheumatol; 2014 Nov; 24(6):945-8. PubMed ID: 24670134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.